- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00543010
MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
June 11, 2015 updated by: Merck Sharp & Dohme LLC
A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Study Overview
Study Type
Interventional
Enrollment (Actual)
247
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- You are taking at least one medication for high blood sugar
- Age 21 to 80
Exclusion Criteria:
- History of Type 1 Diabetes Mellitus
- Currently on estrogen replacement therapy regimen
- Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
- Having surgery 30 days before starting the study
- Have taken any other investigational drug in the past 90 days
- Have Hepatitis B or C
- Active liver or gallbladder disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2002
Primary Completion (Actual)
November 1, 2003
Study Completion (Actual)
November 1, 2003
Study Registration Dates
First Submitted
October 5, 2007
First Submitted That Met QC Criteria
October 11, 2007
First Posted (Estimate)
October 12, 2007
Study Record Updates
Last Update Posted (Estimate)
June 12, 2015
Last Update Submitted That Met QC Criteria
June 11, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0767-018
- 2007_644
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on MK0767
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDyslipidemia | Diabetes Mellitus, Type II
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedMetabolic X Syndrome Dyslipidemia